New pharmacotherapy for hepatitis C

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 3, 2012, Pages 294-305

  Assis, D N ^a   Lim, J K ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; NONSTRUCTURAL PROTEIN 5A; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; POLYMERASE; PROTEINASE; RIBAVIRIN; TELAPREVIR; UNCLASSIFIED DRUG; VIRUS ENZYME;

ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MEDICAL DECISION MAKING; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; VIRUS GENOME;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER; OLIGOPEPTIDES; PROLINE;

EID: 84865414920     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.103     Document Type: Article

References (56)

1. Armstrong, G.L., Wasley, A., Simard, E.P., McQuillan, G.M., Kuhnert, W.L. & Alter, M.J. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann. Intern. Med. 144, 705-714 (2006). (Pubitemid 46780630)
2. Wise, M., Bialek, S., Finelli, L., Bell, B.P. & Sorvillo, F. Changing trends in hepatitis C-related mortality in the United States, 1995-2004. Hepatology 47, 1-8 (2008).
3. MMWR: Surveillance Summaries. Morbidity and Mortality Weekly Report 58, 1-27 (2009).
4. Telaprevir (Incivek) and Boceprecir (Victrelis) for chronic hepatitis C. The Medical Letter 53, 57-59 (2011).
5. Lok, A.S. et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 366, 216-224 (2012).
6. Choo, Q.L., Kuo, G., Weiner, A.J., Overby, L.R., Bradley, D.W. & Houghton, M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244, 359-362 (1989). (Pubitemid 19117877)
7. Kleinman, S. et al. Increased detection of hepatitis C virus (HCV)-infected blood donors by a multiple-antigen HCV enzyme immunoassay. Transfusion 32, 805-813 (1992). (Pubitemid 23001623)
8. Seef, L.B. Natural history of hepatitis C. Am. J. Med. 107, 10S-15S (1999).
9. Liang, T.J., Rehermann, B., Seef, L.B. & Hoofnagle, J.H. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med. 132, 296-305 (2000). (Pubitemid 30106261)
10. Poynard, T., Bedossa, P. & Opolon, P. Natural history of liver fbrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349, 825-832 (1997). (Pubitemid 27129209)
11. Powell, E.E., Jonsson, J.R. & Clouston, A.D. Steatosis: co-factor in other liver diseases. Hepatology 42, 5-13 (2005). (Pubitemid 40911303)
12. Ghany, M.G., Strader, D.B., Thomas, D.L. & Seef, L.B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49, 1335-1374 (2009).
13. Rosen, H.R. Clinical practice. Chronic hepatitis C infection. N. Engl. J. Med. 364, 2429-2438 (2011).
14. Nainan, O.V. et al. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology 131, 478-484 (2006). (Pubitemid 44142463)
15. Kurosaki, M., Enomoto, N., Marumo, F. & Sato, C. Rapid sequence variation of the hypervariable region of hepatitis C virus during the course of chronic infection. Hepatology 18, 1293-1299 (1993). (Pubitemid 23348412)
16. Weiner, A.J. et al. Variable and hypervariable domains are found in the regions of HCV corresponding to the favivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 180, 842-848 (1991).
17. Virgin, H.W., Wherry, E.J. & Ahmed, R. Redefning chronic viral infection. Cell 138, 30-50 (2009).
18. Chemello, L., Cavalletto, L., Bernardinello, E., Guido, M., Pontisso, P. & Alberti, A. The efect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J. Hepatol. 23 (suppl. 2), 8-12 (1995). (Pubitemid 26048737)
19. Fried, M.W. et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347, 975-982 (2002).
20. Davis, G.L., Wong, J.B., McHutchison, J.G., Manns, M.P., Harvey, J. & Albrecht, J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 38, 645-652 (2003). (Pubitemid 37052151)
21. Shifman, M.L. et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med. 357, 124-134 (2007).
22. Kramer, J.R., Kanwal, F., Richardson, P., Mei, M. & El-Serag, H.B. Gaps in the achievement of efectiveness of HCV treatment in national VA practice. J. Hepatol. 56, 320-325 (2012).
23. Ge, D. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399-401 (2009).
24. Charlton, M.R. et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 53, 317-324 (2011).
25. Victrelis™ (boceprevir) [package insert]. Whitehouse Station, NJ: Schering Corporation, 2011.
26. Incivek™ (telaprevir) [package insert]. Cambridge, MA: Vertex Pharmaceuticals, 2011.
27. McHutchison, J.G. et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 360, 1827-1838 (2009).
28. Hézode, C. et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 360, 1839-1850 (2009).
29. Jacobson, I.M. et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364, 2405-2416 (2011).
30. Sherman, K.E. et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N. Engl. J. Med. 365, 1014-1024 (2011).
31. Zeuzem, S. et al. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 364, 2417-2428 (2011).
32. Kwo, P.Y. et al. Efcacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 376, 705-716 (2010).
33. Poordad, F. et al. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364, 1195-1206 (2011).
34. Bacon, B.R. et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 364, 1207-1217 (2011).
35. Gane, E.J. et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 376, 1467-1475 (2010).
36. Garber, K. Hepatitis C: move over interferon. Nat. Biotechnol. 29, 963-966 (2011).
37. Barth, H. Insights into the role of interferon lambda in hepatitis C virus infection. J. Hepatol. 54, 844-847 (2011).
38. Zeuzem, S., Aurora, S., Bacon, B., Box, T., Charlton, M. & Diago, M. Pegylated interferon lambda (PegIFN-l) shows superior viral response with improved safety and tolerability versus PegIFNa-2a in HCV patients (G1/2/3/4): emerger phase IIb through week 12. J Hepatol. 54, S538 (2011) (A1360).
39. Sulkowski, M.S., Ceasu, E., Asselah, T., Caruntu, F.A., Lalezari, J. & Ferenci, P. SILEN-C1: sustained virologic response (SVR) and safety of BI201335 combined with peginterferon alpha-2a and ribavirin (P/R) in treatment-naïve patients with chronic genotype 1 HCV infection. J Hepatol. 54, S27 (2011) (A60).
40. Fried, M., Buti, M., Dore, G.J., Flisiak, R., Ferenci, P. & Jacobson, I.M. TMC435 in combination with peginterferon and ribavirin in treatment-naïve HCV genotype 1 patients: fnal analysis of the PILLAR phase IIb study. Hepatology 54, 1429 (2011) (LB 5).
41. Lalezari, J., Hazan, L., Kankam, M., Lawitz, E., Poordad, F. & Araya, V. High rapid virologic response (RVR) with ACH-1625 daily dosing plus PegIFN-alpha 2a/RBV in a 28-day phase 2a trial. Hepatology 54, 992 (2011) (A1341).
42. Lawitz, E., Lalezari, J., Hassanein, T., Kowdley, K.V., Poordad, F. & Sheikh, A.M. Once-daily PSI-7977 plus peg/RBV in treatment-naïve patients with HCV GT1: robust end of treatment response rates are sustained post-treatment. Hepatology 54, 472 (2011) (Abstract 225).
43. Pockros, P., Jensen, D., Tsai, N., Taylor, R.M., Ramji, A. & Cooper, C. First SVR data with the nucleoside analogue polymerase inhibitor mericitabine (RG17128) combined with peginterferon/ribavirin in treatment-naïve HCV G1/4 patients: interim analysis from the JUMP-C trial. J Hepatol. 54, S538 (2011) (Abstract 1359).
44. Nelson, D.R., Gane, E.J., Jacobson, I.M., Di Bisceglie, A.M., Alves, K. & Koziel, M.J. VX-222/telaprevir in combination with peginterferon-alpha-2a and ribavirin in treatment-naïve genotype 1 HCV patients treated for 12 weeks: ZENITH study, SVR12 interim analysis. Hepatology 54, 1435 (2011) (Abstract LB-14).
45. Lawitz, E., Rodriguez-Torres, M., Rustgi, V.K., Hassanein, T., Rahimy, M.H. & Crowley, C.A. Safety and antiviral activity of ANA598 in combination with pegylated interferon α2a plus ribavirin in treatment-naïve genotype-1 chronic HCV patients. Hepatology 52, 334 (2010) (Abstract 31).
46. Pol, S., Ghalib, RH., Rustgi, VK., Martorell, C., Everson, GT.et al. & Tatum, H.A. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-fnding, phase 2a trial. Lancet Infect Dis. 2012 Jun 15 [Epub ahead of print]. DOI: 10.1016/S1473-3099 (12) 70138-X.
47. Flisiak, R., Pawlotsky, J.M., Crabbe, R., Calistru, P.I., Kryczka, W. & Haussinger, D. Once daily alisporivir (DEB025) plus peginalpha2a/ribavirin results in superior sustained virologic response (SVR24) in chronic hepatitis C genotype 1 treatment naïve patients. J Hepatol. 54, S2 (2011) (Abstract 4).
48. Thomas, E., Feld, J.J., Li, Q., Hu, Z., Fried, M.W. & Liang, T.J. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology 53, 32-41 (2011).
49. Zeuzem, S., Buggisch, P., Agarwal, K., Manns, M.P., Marcellin, P. & Foster, G.R. Dual, triple, and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) or pegIFN/RBV for up to 28 days in treatment naïve, genotype 1 HCV subjects. Hepatology 52, 400 (2010) (Abstract LB-1).
50. Iacobellis, A. et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J. Hepatol. 46, 206-212 (2007). (Pubitemid 44959155)
51. Ghany, M.G., Nelson, D.R., Strader, D.B., Thomas, D.L. & Seef, L.B. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54, 1433-1444 (2011).
52. Graham, C.S. et al. Infuence of human immunodefciency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin. Infect. Dis. 33, 562-569 (2001). (Pubitemid 32709592)
53. Carrat, F. et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 292, 2839-2848 (2004). (Pubitemid 39628231)
54. FDA. Victrelis (boceprevir) and Ritonavir-Boosted Human Immunodefciency Virus (HIV) Protease Inhibitor Drugs: Drug Safety Communication-Drug Interactions http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm291144.htm. Accessed 27 February 2012.
55. Firpi, R.J. et al. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transpl. 15, 1063-1071 (2009).
56. Garg, V., van Heeswijk, R., Lee, J.E., Alves, K., Nadkarni, P. & Luo, X. Efect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 54, 20-27 (2011).